Elixirgen Scientific Japan Awarded Top 10 CDMOs in APAC 2023

Fujisawa, Japan (December 07, 2023) – Elixirgen Scientific Japan, Inc (EsJ), a Japanese provider of synthetic mRNA contract development and manufacturing services, was awarded TOP 10 CDMOs in APAC - 2023 by Pharma Tech Outlook.

Recognized for its excellence in delivering innovative and high-quality solutions in mRNA manufacturing, EsJ has demonstrated significant advancements in this field since its inception of CDMO (Contract Development and Manufacturing Organization) services in September 2021. These advancements have played a pivotal role in achieving this prestigious recognition. By providing high-quality mRNA, we will support pharmaceutical industries to accelerate R&D for mRNA medicine such as vaccines.

This esteemed recognition by Pharma Tech Outlook is based on several key factors, including EsJ's state-of-the-art technology, commitment to quality, and impactful contributions to the pharmaceutical industry. The award highlights EsJ's efforts in enhancing the efficiency and scalability of mRNA manufacturing processes, making significant strides in the field of biotechnology.

For more details on this recognition and insights into Elixirgen Scientific Japan's contribution to the field, please visit: https://cdmo-apac.pharmatechoutlook.com/vendors/top-cdmos-in-apac.html

Elixirgen Scientific Japan is a biotechnology company engaged in contract manufacturing of synthetic mRNA and stem cell-related products and services. Based on its technology for synthesizing mRNA in a cGMP-compliant environment, which is the standard for manufacturing and quality control of pharmaceutical products, and its technology for reproducibly inducing differentiation from iPS cells into various types of cells in about one week, the company aims to improve the quality of people's lives by supporting faster and lower-cost drug discovery. With a vision to revolutionize the field of regenerative medicine and drug development, EsJ continues to innovate and expand its capabilities, aspiring to be at the forefront of biotechnological and pharmaceutical advancements.

For more information, contact [email protected].